Shifting risk‐stratified early prostate cancer detection to a primary healthcare setting
Open Access
- 19 December 2022
- journal article
- research article
- Published by Wiley in BJU International
- Vol. 131 (5) , 596-601
Abstract
Objective: To evaluate the feasibility of multivariable risk stratification for early prostate cancer (PCa) detection in a primary healthcare diagnostic facility with regard to its effects on the referral rate and subsequent PCa diagnoses compared to a PSA threshold of 3.0 ng/mL as the current referral indicator. Patients and Methods: In 2014, the Erasmus MC Cancer Institute and the primary healthcare diagnostic facility STAR‐SHL (located in Rotterdam city centre) initiated this observational study, in which general practitioners (GPs) could refer men who wished to undergo PCa screening to STAR‐SHL for consultation by specially trained personnel. Referral recommendations to secondary healthcare were based on the outcome of application of the Rotterdam Prostate Cancer Risk Calculator (RPCRC) and were compared to the current Dutch GPs' PSA referral threshold of 3.0 ng/mL. For data collection on PCa diagnoses, the study cohort was linked to the Dutch nationwide pathology databank (PALGA). Results: Between January 2014 and February 2021, 507 men were referred for consultation and in 495 men prostate‐specific antigen (PSA) was tested. The median (interquartile range) follow‐up from consultation to PALGA linkage was 43 (25–65) months. In total, 279 men (56%) had a PSA level ≥3.0 ng/mL, of whom 68% (95% confidence interval [95% CI] 63–74) were considered at low risk according to the RPCRC. Within 1 year after consultation, one of these men (0.52%; 95% CI 0.092–2.9) was diagnosed with clinically significant (cs)PCa (i.e., International Society of Urological Pathology Grade Group ≥2). Thereafter, another four (2.1%; 95% CI 0.82–5.3) low‐risk men were diagnosed with csPCa. Of the high‐risk men who were biopsied within 1 year after consultation ( n = 61), 77% (95% CI 65–86) were diagnosed with PCa and 49% (95% CI 37–61) with csPCa. Conclusion: In a primary healthcare diagnostic facility, the RPCRC could reduce up to 68% of referrals to secondary healthcare, as compared to a PSA referral threshold of 3.0 ng/mL. Deploying the RPCRC in this setting resulted in a high csPCa detection rate in those men biopsied. This strategy can be considered safe since the observational data showed low proportions of csPCa among men at low risk.Keywords
This publication has 13 references indexed in Scilit:
- Prediction of High-grade Prostate Cancer Following Multiparametric Magnetic Resonance Imaging: Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk CalculatorsEuropean Urology, 2019
- Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer MortalityJAMA, 2018
- Multivariable risk-based patient selection for prostate biopsy in a primary health care setting: referral rate and biopsy results from a urology outpatient clinicTranslational Andrology and Urology, 2018
- Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO TrialsAnnals of Internal Medicine, 2017
- The Epidemiology of Benign Prostatic Hyperplasia Associated with Lower Urinary Tract SymptomsUrologic Clinics of North America, 2016
- Opportunistic Testing Versus Organized Prostate-specific Antigen Screening: Outcome After 18 Years in the Göteborg Randomized Population-based Prostate Cancer Screening TrialEuropean Urology, 2015
- The Effect of Benign Lower Urinary Tract Symptoms on Subsequent Prostate Cancer Testing and DiagnosisEuropean Urology, 2013
- A Calculator for Prostate Cancer Risk 4 Years After an Initially Negative Screen: Findings from ERSPC RotterdamEuropean Urology, 2013
- A Risk-Based Strategy Improves Prostate-Specific Antigen–Driven Detection of Prostate CancerEuropean Urology, 2010
- Screening and Prostate-Cancer Mortality in a Randomized European StudyNew England Journal of Medicine, 2009